N-carbamylglutamate
Phase 2Small molecule
N-carbamylglutamate is one of 7 small molecule programs targeting Hyperammonemia. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
10 competitors in Propionic Acidemia
#DrugCompanyPhaseTrials
1Carbaglu
RRECORDATI GROUP
Phase 3
Glutamine
SanofiPhase 1
Mrna-3927
ModernaPhase 2
N-carbamylglutamate
MMendel Tuchman
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Propionic Acidemia1 trial
Inborn Errors of Metabolism1 trial
Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate
Withdrawn·—·Phase 2·NCT01341379
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for N-carbamylglutamate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMendel Tuchman